Alpha2-Antiplasmin: The Devil You Don't Know in Cerebrovascular and Cardiovascular Disease

Fibrinolysis and Inflammation in Venous Thrombus Resolution

(2019) Subhradip Mukhopadhyay et al.   Frontiers in Immunology

ST-segment elevation myocardial infarction

(2019) Birgit Vogel et al.   Nature Reviews Disease Primers

Venous stasis-induced fibrinolysis prevents thrombosis in mice: role of α2-antiplasmin

(2019) Satish Singh et al.   BLOOD

Ischaemic stroke

(2019) Bruce C. V. Campbell et al.   Nature Reviews Disease Primers

Matrix Metalloproteinase-9 Mediates the Deleterious Effects of α2-Antiplasmin on Blood–Brain Barrier Breakdown and Ischemic Brain Injury in Experimental Stroke

(2018) Satish Singh et al.   NEUROSCIENCE

A novel allele variant of the SERPINF2 gene responsible for severe plasmin inhibitor (α 2 -antiplasmin) deficiency in an Italian patient

(2018) Silvana Viganò et al.   THROMBOSIS RESEARCH

Pulmonary embolism

(2018) Menno V. Huisman et al.   Nature Reviews Disease Primers

Blood-derived plasminogen drives brain inflammation and plaque deposition in a mouse model of Alzheimer’s disease

(2018) Sarah K. Baker et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The fibrinolysis inhibitor α2-antiplasmin restricts lymphatic remodelling and metastasis in a mouse model of cancer

(2017) Sophie Paquet-Fifield et al.   GROWTH FACTORS

Plasmin (Human) Administration in Acute Middle Cerebral Artery Ischemic Stroke: Phase 1/2a, Open-Label, Dose-Escalation, Safety Study

(2017) Peter J. Mitchell et al.   Journal of Stroke & Cerebrovascular Diseases

Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice

(2017) C. Tersteeg et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Inhibition of Fibrinolysis by Coagulation Factor XIII

(2017) Dingeman C. Rijken et al.   Biomed Research International

Plasmin (Human) Administration in Acute Middle Cerebral Artery Ischemic Stroke: Phase 1/2a, Open-Label, Dose-Escalation, Safety Study

(2017) Peter J. Mitchell et al.   Journal of Stroke & Cerebrovascular Diseases

Releasing the Brakes on the Fibrinolytic System in Pulmonary EmboliClinical Perspective

(2016) Satish Singh et al.   CIRCULATION

Global Burden of Thrombosis: Table.

(2016) Aaron M. Wendelboe et al.   CIRCULATION RESEARCH

Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII

(2016) D. C. Rijken et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

α2-Antiplasmin: New Insights and Opportunities for Ischemic Stroke

(2016) Aiilyan Houng et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Natural heterogeneity of  2-antiplasmin: functional and clinical consequences

(2015) S. Abdul et al.   BLOOD

Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin  -chain crosslinking

(2015) J. R. Byrnes et al.   BLOOD

Tissue-based map of the human proteome

(2015) M. Uhlen et al.   SCIENCE

Venous thrombosis

(2015) Alisa S. Wolberg et al.   Nature Reviews Disease Primers

α2 Antiplasmin and Microvascular Thrombosis in Ischemic Stroke

(2014) Enming J. Su et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Microvascular Thrombosis, Fibrinolysis, Ischemic Injury, and Death After Cerebral Thromboembolism Are Affected by Levels of Circulating α2-Antiplasmin

(2014) Guy L. Reed et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Reversing the deleterious effects of α2-antiplasmin on tissue plasminogen activator therapy improves outcomes in experimental ischemic stroke

(2014) Aiilyan K. Houng et al.   EXPERIMENTAL NEUROLOGY

Factor XIII activity mediates red blood cell retention in venous thrombi

(2014) Maria M. Aleman et al.   JOURNAL OF CLINICAL INVESTIGATION

Altered Behavior in Mice with Deletion of the Alpha2-Antiplasmin Gene

(2014) Eri Kawashita et al.   PLoS One

α2AP mediated myofibroblast formation and the development of renal fibrosis in unilateral ureteral obstruction

(2014) Yosuke Kanno et al.   Scientific Reports

Ocriplasmin: A Review of Its Use in Patients with Symptomatic Vitreomacular Adhesion

(2013) Yahiya Y. Syed et al.   DRUGS

Involvement of α2-antiplasmin in dendritic growth of hippocampal neurons

(2013) Eri Kawashita et al.   JOURNAL OF NEUROCHEMISTRY

The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis

(2013) E. L. Hethershaw et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Alpha2-antiplasmin regulates the development of dermal fibrosis in mice by prostaglandin F2αsynthesis through adipose triglyceride lipase/calcium-independent phospholipase A2

(2012) Yosuke Kanno et al.   ARTHRITIS AND RHEUMATISM

Safety of catheter-delivered plasmin in patients with acute lower extremity arterial or bypass graft occlusion: phase I results

(2012) V. J. MARDER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

The hyperfibrinolytic state of mice with combined thrombin-activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 gene deficiency is critically dependent on TAFI deficiency

(2012) E. VERCAUTEREN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

The antifibrinolytic function of factor XIII is exclusively expressed through  2-antiplasmin cross-linking

(2011) S. R. Fraser et al.   BLOOD

Contribution of Conserved Lysine Residues in the α2-Antiplasmin C Terminus to Plasmin Binding and Inhibition

(2011) Bernadine G. C. Lu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Activators and inhibitors of the plasminogen system in Alzheimer’s disease

(2011) Rachel Barker et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Enhancement of fibrinolysis by inhibiting enzymatic cleavage of precursor α2-antiplasmin

(2011) K. N. LEE et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men

(2010) M. E. Meltzer et al.   BLOOD

Novel Hemostatic Factor Levels and Risk of Ischemic Stroke: The Atherosclerosis Risk in Communities (ARIC) Study

(2010) M. Fareed K. Suri et al.   CEREBROVASCULAR DISEASES

Pathophysiology of thrombotic thrombocytopenic purpura

(2010) Han-Mou Tsai   INTERNATIONAL JOURNAL OF HEMATOLOGY

I-TASSER: a unified platform for automated protein structure and function prediction

(2010) Ambrish Roy et al.   Nature Protocols

Using Substrate Specificity of Antiplasmin-Cleaving Enzyme for Fibroblast Activation Protein Inhibitor Design

(2009) Kyung N. Lee et al.   BIOCHEMISTRY

Addition of a sequence from α2-antiplasmin transforms human serum albumin into a blood clot component that speeds clot lysis

(2009) William P Sheffield et al.   BMC BIOTECHNOLOGY

Neutralization of α2-antiplasmin by microplasmin: A randomized, double-blind, placebo-controlled, ascending-dose study in healthy male volunteers

(2009) Steve Pakola et al.   CLINICAL THERAPEUTICS

Direct fibrinolytic agents: biochemical attributes, preclinical foundation and clinical potential

(2009) V. J. MARDER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Randomized, Placebo-Controlled, Dose-Ranging Clinical Trial of Intravenous Microplasmin in Patients With Acute Ischemic Stroke

(2009) Vincent N.S. Thijs et al.   STROKE

Alpha2-Antiplasmin Is a Critical Regulator of Angiotensin II–Mediated Vascular Remodeling

(2008) YongZhong Hou et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY